title: Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
abstract: The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer.
authors: Division of Medical Oncology, Duke Cancer Institute, Duke University, DUMC Box 102002, Durham, North Carolina 27710, USA.
authors: Rhonda L
authors: RL
authors: Bitting
authors: Andrew J
authors: AJ
authors: Armstrong
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006801:Humans; D008297:Male; D058539:Phosphatidylinositol 3-Kinase / Q000378:metabolism*; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; C546842:MTOR protein, human; D058539:Phosphatidylinositol 3-Kinase; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases
keywords: Akt; PI3K inhibitors; PI3K pathway; androgen receptor signaling; castration-resistant prostate cancer (CRPC); combination therapy; mTOR